{
    "hands_on_practices": [
        {
            "introduction": "Effective management begins with an accurate diagnosis, which can be challenging when serological results are discordant. This exercise  presents a common clinical puzzle: a reactive treponemal test with a nonreactive nontreponemal test in a pregnant, HIV-coinfected patient. Mastering this scenario requires applying foundational knowledge of syphilis serology to make a safe and evidence-based decision, prioritizing fetal protection when prior treatment history is uncertain.",
            "id": "4457682",
            "problem": "A pregnant patient presents in the second trimester for routine follow-up in a sexually transmitted infections clinic. She is a gravida 1 para 0 at 18 weeks of gestation. She reports being diagnosed with Human Immunodeficiency Virus (HIV) infection 3 years ago and is currently on antiretroviral therapy with a recent cluster of differentiation 4 (CD4) cell count of 650 cells/$\\text{mm}^3$ and an HIV ribonucleic acid (RNA) viral load $50$ copies/$\\text{mL}$; she has had no opportunistic infections. She denies genital ulcers, rashes, or neurologic symptoms. She has no drug allergies. She recalls receiving “a shot” for “an infection” approximately 5 years ago but has no records of what was treated or which medication was used. Her partner’s infection status is unknown.\n\nInitial prenatal laboratory tests obtained at 10 weeks included a treponemal Enzyme Immunoassay (EIA) that was reactive and a Rapid Plasma Reagin (RPR) that was nonreactive. Repeat serology today at 18 weeks again shows a reactive treponemal test (Treponema pallidum particle agglutination, TP-PA, reactive) and a nonreactive RPR. The Venereal Disease Research Laboratory (VDRL) test is not performed. Fetal ultrasound is unremarkable.\n\nUsing only the following foundational facts and definitions, determine the most appropriate interpretation and next-step management: treponemal tests (such as EIA, TP-PA, fluorescent treponemal antibody absorption) detect antibodies specific to Treponema pallidum and tend to remain reactive for life after infection regardless of treatment; nontreponemal tests (such as RPR, VDRL) detect anticardiolipin antibodies that correlate imperfectly with disease activity and can be nonreactive in very early primary syphilis before seroconversion and in late latent syphilis; in pregnancy, documented treponemal reactivity without documented prior adequate therapy warrants treatment to prevent congenital syphilis; benzathine penicillin G is the only proven therapy to prevent fetal infection and is indicated for all stages, with dosing dependent on stage; HIV coinfection does not change penicillin-based regimens but necessitates careful follow-up; lumbar puncture is reserved for neurologic symptoms or treatment failure.\n\nWhich option best reflects the correct interpretation of the discordant serology and the optimal management in this pregnant patient with HIV coinfection?\n\nA. Past adequately treated syphilis; no therapy is required; repeat screening postpartum only.\n\nB. Very early primary syphilis; repeat RPR in 2 weeks and give a single dose of benzathine penicillin G $2.4\\times 10^6$ units intramuscularly today.\n\nC. Late latent syphilis or syphilis of unknown duration; treat with benzathine penicillin G $2.4\\times 10^6$ units intramuscularly weekly for 3 doses; no lumbar puncture now; monitor quantitative RPR monthly during pregnancy and ensure partner evaluation.\n\nD. Because of HIV coinfection and discordant serology, perform cerebrospinal fluid examination now and treat with intravenous aqueous penicillin G for 10–14 days even without neurologic signs.\n\nE. Past syphilis with low risk of congenital transmission; use doxycycline 100 mg orally twice daily for 28 days due to nonreactive RPR and avoid penicillin in pregnancy unless titers rise.",
            "solution": "The user wants me to validate and solve a clinical problem regarding the management of syphilis in a pregnant patient with HIV co-infection.\n\n### Step 1: Extract Givens\n-   **Patient Profile**: Pregnant female, gravida 1 para 0, at 18 weeks of gestation.\n-   **HIV Status**: Diagnosed 3 years ago, on antiretroviral therapy. Recent CD4 cell count: 650 cells/$\\text{mm}^3$. HIV RNA viral load: $50$ copies/$\\text{mL}$. No history of opportunistic infections.\n-   **Syphilis History**: Recalls receiving \"a shot\" for \"an infection\" approximately 5 years ago. No records of diagnosis or treatment are available.\n-   **Symptoms**: Denies genital ulcers, rashes, or neurologic symptoms.\n-   **Allergies**: No drug allergies.\n-   **Partner Status**: Unknown.\n-   **Laboratory Data**:\n    -   At 10 weeks gestation: Treponemal Enzyme Immunoassay (EIA) was reactive; Rapid Plasma Reagin (RPR) was nonreactive.\n    -   At 18 weeks gestation: Treponema pallidum particle agglutination (TP-PA) is reactive; RPR is nonreactive.\n    -   Venereal Disease Research Laboratory (VDRL) test not performed.\n-   **Imaging**: Fetal ultrasound is unremarkable.\n-   **Foundational Facts for Reasoning**:\n    1.  Treponemal tests (e.g., EIA, TP-PA) detect specific antibodies to *Treponema pallidum* and usually remain reactive for life after infection, regardless of treatment.\n    2.  Nontreponemal tests (e.g., RPR, VDRL) detect anticardiolipin antibodies, correlate with disease activity, and can be nonreactive in very early primary syphilis and in late latent syphilis.\n    3.  In pregnancy, documented treponemal reactivity without documented prior adequate therapy warrants treatment to prevent congenital syphilis.\n    4.  Benzathine penicillin G is the only proven therapy to prevent fetal infection and is indicated for all stages; dosing depends on the stage.\n    5.  HIV coinfection does not alter penicillin-based regimens but requires careful follow-up.\n    6.  Lumbar puncture is reserved for patients with neurologic symptoms or those experiencing treatment failure.\n\n### Step 2: Validate Using Extracted Givens\nThe problem statement is evaluated for validity.\n\n-   **Scientifically Grounded**: The problem presents a classic clinical scenario in infectious disease management, specifically concerning syphilis and HIV in pregnancy. The diagnostic tests (EIA, RPR, TP-PA), clinical presentation, and treatment principles are consistent with established medical guidelines (e.g., from the U.S. Centers for Disease Control and Prevention). The foundational facts provided are accurate and reflect standard medical knowledge. The scenario is scientifically and medically sound.\n-   **Well-Posed**: The problem is well-posed. It provides sufficient clinical data and a set of explicit \"foundational facts\" to guide reasoning. The information allows for a logical deduction of the most likely diagnosis and the standard-of-care management plan.\n-   **Objective**: The language is objective and clinical. It is free from ambiguity, subjective claims, or bias.\n\n### Step 3: Verdict and Action\nThe problem is valid. It is a well-structured clinical reasoning task based on sound medical principles. I will proceed with the solution.\n\n### Solution Derivation\nThe patient's clinical situation must be interpreted by synthesizing the serological data with her history and pregnancy status, strictly adhering to the provided foundational facts.\n\n1.  **Interpretation of Serological Tests**: The patient has a reactive treponemal test, confirmed on two separate occasions (10 weeks and 18 weeks) with two different methods (EIA and TP-PA). According to foundational fact #1, this indicates that the patient has had a syphilis infection at some point in her life. The nontreponemal test (RPR) is consistently nonreactive. Foundational fact #2 notes that a nonreactive RPR can be seen in two main scenarios: very early primary syphilis (before the nontreponemal antibodies rise) or late latent syphilis.\n\n2.  **Differential Diagnosis and Staging**:\n    -   **Very Early Primary Syphilis**: This is unlikely. The RPR has been nonreactive over an 8-week interval (from week 10 to week 18). In an active new infection, the RPR would be expected to become reactive during this period. The patient also denies symptoms of primary syphilis, such as genital ulcers.\n    -   **Past, Adequately Treated Syphilis**: This condition would present with a reactive treponemal test and a nonreactive RPR (seroreversion). However, the patient's history of treatment is a vague recollection and is not documented. Foundational fact #3 is explicit and critical here: \"in pregnancy, documented treponemal reactivity *without documented prior adequate therapy* warrants treatment to prevent congenital syphilis.\" Since her treatment cannot be verified, she must be managed as if she is untreated or inadequately treated.\n    -   **Late Latent Syphilis or Syphilis of Unknown Duration**: This diagnosis is most consistent with the clinical picture. The serological pattern (reactive treponemal test, nonreactive nontreponemal test) is common in late latent syphilis (per fact #2). As she has no signs or symptoms of primary, secondary, or tertiary syphilis, and the timing of infection is unknown, she is classified as having syphilis of unknown duration, which is managed identically to late latent syphilis.\n\n3.  **Management Plan**:\n    -   **Treatment Indication**: Based on fact #3, treatment is mandatory to prevent congenital syphilis due to the reactive treponemal test and lack of documented adequate therapy.\n    -   **Choice of Drug**: Fact #4 states that \"benzathine penicillin G is the *only* proven therapy to prevent fetal infection.\" The patient has no drug allergies, so penicillin is the clear choice.\n    -   **Dosing Regimen**: Fact #4 also states that \"dosing [is] dependent on stage.\" The standard regimen for late latent syphilis or syphilis of unknown duration is a total of 7.2 million units of benzathine penicillin G, administered as three separate doses of $2.4 \\times 10^6$ units intramuscularly at 1-week intervals.\n    -   **Role of HIV Co-infection**: Fact #5 clarifies that \"HIV coinfection does not change penicillin-based regimens but necessitates careful follow-up.\" The patient's well-controlled HIV (CD4 650 cells/$\\text{mm}^3$, undetectable viral load) further supports using the standard regimen without modification.\n    -   **Lumbar Puncture (LP)**: Fact #6 specifies that an LP is for neurologic symptoms or treatment failure. This patient has no neurologic symptoms and has not yet been treated, so there is no indication for an LP at this time.\n    -   **Follow-up**: Careful follow-up, including monitoring of nontreponemal titers (even if starting from nonreactive) and partner notification/evaluation, is essential, as alluded to in fact #5.\n\nCombining these points, the correct course of action is to diagnose the patient with late latent syphilis or syphilis of unknown duration and treat her with a 3-week course of benzathine penicillin G.\n\n### Option-by-Option Analysis\n\n**A. Past adequately treated syphilis; no therapy is required; repeat screening postpartum only.**\n-   **Analysis**: This is incorrect. It ignores the explicit directive in foundational fact #3 that treatment is required in pregnancy for a patient with a reactive treponemal test but no documentation of adequate prior therapy. Withholding treatment would pose an unacceptable risk of congenital syphilis to the fetus.\n-   **Verdict**: **Incorrect**.\n\n**B. Very early primary syphilis; repeat RPR in 2 weeks and give a single dose of benzathine penicillin G $2.4\\times 10^6$ units intramuscularly today.**\n-   **Analysis**: This diagnosis is inconsistent with the stable nonreactive RPR over an 8-week period and the absence of symptoms. Furthermore, the single-dose penicillin regimen is for primary, secondary, or early latent syphilis, and would be inadequate treatment if the patient has late latent syphilis, thereby failing to reliably prevent congenital syphilis.\n-   **Verdict**: **Incorrect**.\n\n**C. Late latent syphilis or syphilis of unknown duration; treat with benzathine penicillin G $2.4\\times 10^6$ units intramuscularly weekly for 3 doses; no lumbar puncture now; monitor quantitative RPR monthly during pregnancy and ensure partner evaluation.**\n-   **Analysis**: This option is fully consistent with the derivation. It correctly identifies the stage as late latent syphilis or syphilis of unknown duration, proposes the correct treatment regimen (three weekly doses of benzathine penicillin G), correctly defers lumbar puncture according to the provided facts, and includes appropriate follow-up management.\n-   **Verdict**: **Correct**.\n\n**D. Because of HIV coinfection and discordant serology, perform cerebrospinal fluid examination now and treat with intravenous aqueous penicillin G for 10–14 days even without neurologic signs.**\n-   **Analysis**: This describes management for neurosyphilis. According to foundational fact #6, a CSF examination (lumbar puncture) is not indicated without neurologic signs or treatment failure. While HIV co-infection can be a risk factor for neurosyphilis, current guidelines do not recommend routine LP for all co-infected individuals, especially those who are asymptomatic and immunologically stable (CD4  350 cells/$\\text{mm}^3$). This approach is overly aggressive and not supported by the provided facts.\n-   **Verdict**: **Incorrect**.\n\n**E. Past syphilis with low risk of congenital transmission; use doxycycline 100 mg orally twice daily for 28 days due to nonreactive RPR and avoid penicillin in pregnancy unless titers rise.**\n-   **Analysis**: This option is fundamentally flawed. First, the risk of congenital transmission is significant in untreated maternal syphilis, even in the latent stage. Second, doxycycline is a tetracycline antibiotic, which is contraindicated in the second and third trimesters of pregnancy due to adverse effects on fetal development. Third, foundational fact #4 explicitly identifies benzathine penicillin G as the *only* proven therapy to prevent fetal infection. Using an alternative is inappropriate and dangerous.\n-   **Verdict**: **Incorrect**.",
            "answer": "$$\\boxed{C}$$"
        },
        {
            "introduction": "Once a diagnosis is established, successful treatment requires meticulous planning and adherence, especially in a multi-dose regimen. This problem  simulates a real-world challenge where a patient has missed a dose, forcing you to integrate two critical timing rules: the maximum allowable interval between doses and the required treatment-free window before delivery. Solving this requires you to not only identify the need to restart therapy but also to perform a backward calculation to create a viable new schedule, a crucial skill in high-risk obstetric care.",
            "id": "4457706",
            "problem": "A 29-year-old gravida 2 para 1 at 32 weeks gestation with Human Immunodeficiency Virus (HIV) co-infection on antiretroviral therapy presents for continuation of treatment of late latent syphilis. She is receiving intramuscular benzathine penicillin G following the regimen recommended for late latent syphilis or syphilis of unknown duration in pregnancy and HIV co-infection: 3 doses administered at 7-day intervals. She received dose 1 17 days ago, missed dose 2, and presents today requesting guidance.\n\nUse the following foundational facts:\n- In pregnancy, for regimens requiring multiple weekly doses of benzathine penicillin G, any inter-dose interval greater than 9 days necessitates restarting the entire series to ensure adequate maternal and fetal treatment.\n- The regimen for persons with HIV co-infection is the same as for persons without HIV but demands strict adherence and close follow-up.\n- Adequate maternal therapy to prevent congenital syphilis requires completing the full prescribed course at least 30 days before expected delivery.\n- The prescribed interval between doses is 7 days; however, inter-dose gaps must not exceed 9 days.\n\nHer estimated delivery is in 56 days. Determine whether the series must be restarted and design a revised schedule that meets all timing requirements before delivery. Specifically, compute the latest possible day from today, denoted by $t$ in days, to administer the first dose of the restarted series such that the third dose is completed at least 30 days before the estimated delivery and all inter-dose intervals are $\\leq 9$ days. Assume you will schedule each subsequent dose exactly 7 days after the preceding dose. Express your final numeric answer $t$ in days. No rounding is required.",
            "solution": "The problem is first validated to ensure it is scientifically grounded, well-posed, and objective.\n\n### Step 1: Extract Givens\n- Patient: 29-year-old gravida 2 para 1 at 32 weeks gestation.\n- Co-morbidities: Human Immunodeficiency Virus (HIV) co-infection, late latent syphilis.\n- Prescribed regimen: 3 doses of benzathine penicillin G.\n- Standard inter-dose interval: 7 days.\n- Patient history: Dose 1 was administered 17 days ago. Dose 2 was missed. Today is the day of presentation.\n- Rule 1: An inter-dose interval greater than 9 days requires restarting the entire series.\n- Rule 2: Adequate maternal therapy requires completion of the full course at least 30 days before the estimated delivery date.\n- Estimated delivery date: In 56 days from today.\n- Task assumption: A revised schedule will use inter-dose intervals of exactly 7 days.\n- Objective: Determine if the series must be restarted. Compute the latest possible day from today, denoted by $t$ (in days), to administer the first dose of the restarted series, satisfying all constraints.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is a well-defined scheduling and optimization problem grounded in established, albeit simplified, clinical protocols. The givens are internally consistent and provide a complete set of constraints to arrive at a unique solution. The problem can be formalized mathematically and does not violate scientific principles, but rather uses them as axioms. The language is objective and precise. The problem is deemed valid.\n\n### Step 3: Verdict and Action\nThe problem is valid. A detailed solution will be provided.\n\n### Solution Derivation\nThe solution is developed in two parts: first, determining the necessity of restarting the treatment series, and second, calculating the latest possible start date for the new series.\n\nLet $t_{today}$ be the reference point in time, designated as day $0$.\n\n**Part 1: Determine if the series must be restarted.**\nThe patient received her first dose of penicillin 17 days ago. In our time frame, this administration occurred on day $t_{dose1} = -17$. The second dose was scheduled to be administered 7 days later, on day $t_{dose2, scheduled} = -17 + 7 = -10$. This dose was missed.\n\nThe patient presents today, on day $0$, to receive the next dose. The interval between the first dose (administered on day $-17$) and today (day $0$) is $\\Delta t_{actual} = t_{today} - t_{dose1} = 0 - (-17) = 17$ days.\n\nThe problem states that any inter-dose interval greater than 9 days necessitates restarting the entire series. Let the maximum allowed interval be $\\Delta t_{max} = 9$ days.\nWe compare the actual interval to the maximum allowed interval:\n$$ \\Delta t_{actual} = 17 \\text{ days} > \\Delta t_{max} = 9 \\text{ days} $$\nSince the interval of 17 days exceeds the maximum permissible interval of 9 days, the treatment series is no longer valid. Therefore, the entire 3-dose series must be restarted.\n\n**Part 2: Calculate the latest start date for the new series.**\nLet $t$ be the day, relative to today (day $0$), on which the first dose of the new, restarted series is administered. The value of $t$ must be a non-negative integer, $t \\ge 0$. We need to find the maximum possible value of $t$.\n\nThe new series consists of $N_{doses} = 3$ doses.\nThe problem specifies that the new schedule will use an inter-dose interval of $\\Delta t_{schedule} = 7$ days.\n\nThe administration days for the three doses are as follows:\n- Dose 1': on day $t$.\n- Dose 2': on day $t + \\Delta t_{schedule} = t + 7$.\n- Dose 3': on day $(t + 7) + \\Delta t_{schedule} = t + 7 + 7 = t + 14$.\n\nThe course of therapy is considered complete upon the administration of the third and final dose. Thus, the completion day, $D_{complete}$, is:\n$$ D_{complete} = t + 14 $$\n\nThe problem provides two critical temporal constraints:\n1. The estimated delivery date, $D_{delivery}$, is in 56 days. So, $D_{delivery} = 56$.\n2. The full course must be completed at least 30 days before the estimated delivery. Let this pre-delivery window be $W_{pre} = 30$ days.\n\nThis second constraint can be expressed as an inequality:\n$$ D_{delivery} - D_{complete} \\ge W_{pre} $$\nSubstituting the known values and the expression for $D_{complete}$:\n$$ 56 - (t + 14) \\ge 30 $$\n\nWe now solve this inequality for $t$:\n$$ 56 - t - 14 \\ge 30 $$\n$$ 42 - t \\ge 30 $$\nSubtract $42$ from both sides:\n$$ -t \\ge 30 - 42 $$\n$$ -t \\ge -12 $$\nMultiply by $-1$ and reverse the inequality sign:\n$$ t \\le 12 $$\n\nThe inequality $t \\le 12$ indicates that the first dose of the restarted series must be administered on or before day 12 (i.e., within 12 days from today). The problem asks for the *latest possible day* to administer this first dose. This corresponds to the maximum integer value of $t$ that satisfies the inequality.\nThe maximum integer value for $t$ is 12.\n\nLet's verify this solution. If the new series starts on $t=12$:\n- Dose 1' is given on day 12.\n- Dose 2' is given on day $12+7=19$.\n- Dose 3' is given on day $19+7=26$.\nThe therapy is completed on day 26.\nThe estimated delivery is on day 56.\nThe time between completion and delivery is $56 - 26 = 30$ days.\nThis meets the requirement of being \"at least 30 days before\" delivery, as $30 \\ge 30$.\nIf we were to start one day later, at $t=13$, completion would be on day $13+14 = 27$. The time until delivery would be $56 - 27 = 29$ days, which is less than the required 30 days.\nTherefore, the latest possible day to start the new series is 12 days from today.",
            "answer": "$$\\boxed{12}$$"
        },
        {
            "introduction": "When maternal treatment is insufficient to prevent congenital syphilis, the focus shifts to treating the neonate, a scenario demanding utmost precision in drug administration. This practice problem  focuses on the fundamental skill of calculating pediatric drug dosages, accounting for regimen changes that reflect the maturation of a newborn's metabolic pathways. Correctly performing this calculation is a non-negotiable competency, ensuring therapeutic efficacy while minimizing the risk of toxicity in this vulnerable population.",
            "id": "4457632",
            "problem": "A term neonate weighing $3.0$ $\\mathrm{kg}$ is born to a mother with untreated early syphilis and Human Immunodeficiency Virus (HIV) co-infection. The infant meets criteria for treatment of proven congenital syphilis using aqueous crystalline penicillin G, which is dosed as $50,000$ units per $\\mathrm{kg}$ per dose administered intravenously (IV) every 12 hours during the first 7 days of life and every 8 hours thereafter. Using the foundational clinical definitions that relate dose per administration and administration frequency to daily exposure, compute the exact daily amount of aqueous crystalline penicillin G delivered during the two distinct age intervals: the first seven days of life and the period thereafter. Express each daily amount in units per day, provide exact values with no rounding, and present your two results as a row matrix with the first entry corresponding to the first seven days of life and the second entry corresponding to the period thereafter. Do not include units in the boxed final answer; however, regard all values as units per day.",
            "solution": "The problem is valid as it is scientifically grounded in clinical pharmacology, well-posed with all necessary data for a unique solution, and stated using objective, formal language. We can therefore proceed with the calculation.\n\nThe problem requires the computation of the total daily amount of aqueous crystalline penicillin G administered to a neonate during two distinct time intervals. The foundational principle for this calculation is that the total daily amount of a drug is the product of the amount administered per dose and the number of doses administered per day.\n\nLet a variable $m$ represent the mass of the neonate, which is given as $m = 3.0 \\text{ kg}$.\nLet $D$ be the specified dose per kilogram of body mass per administration. The problem states this is $D = 50,000$ units per kg per dose.\n\nFirst, we calculate the amount of penicillin G delivered in a single dose, which we will denote as $A_{dose}$. This amount is constant for both time intervals as it depends only on the neonate's mass and the specified dose per kilogram, neither of which changes between the intervals.\n$$A_{dose} = m \\times D$$\nSubstituting the given values:\n$$A_{dose} = 3.0 \\, \\mathrm{kg} \\times 50,000 \\, \\frac{\\text{units}}{\\mathrm{kg} \\cdot \\text{dose}} = 150,000 \\, \\frac{\\text{units}}{\\text{dose}}$$\n\nNext, we analyze the two distinct age intervals separately to determine the total daily amount.\n\n**Interval 1: The first 7 days of life**\n\nDuring this period, the drug is administered every 12 hours. Let the time interval between doses be $t_1 = 12$ hours. The number of doses per day, $N_1$, can be calculated by dividing the total number of hours in a day (24) by the interval between doses.\n$$N_1 = \\frac{24 \\, \\frac{\\text{hours}}{\\text{day}}}{t_1} = \\frac{24 \\, \\frac{\\text{hours}}{\\text{day}}}{12 \\, \\frac{\\text{hours}}{\\text{dose}}} = 2 \\, \\frac{\\text{doses}}{\\text{day}}$$\nThe total daily amount for the first interval, denoted $T_1$, is the product of the amount per dose and the number of doses per day.\n$$T_1 = A_{dose} \\times N_1$$\n$$T_1 = 150,000 \\, \\frac{\\text{units}}{\\text{dose}} \\times 2 \\, \\frac{\\text{doses}}{\\text{day}} = 300,000 \\, \\frac{\\text{units}}{\\text{day}}$$\n\n**Interval 2: The period thereafter (after the first 7 days)**\n\nDuring this subsequent period, the drug is administered every 8 hours. Let the time interval between doses be $t_2 = 8$ hours. The number of doses per day, $N_2$, is:\n$$N_2 = \\frac{24 \\, \\frac{\\text{hours}}{\\text{day}}}{t_2} = \\frac{24 \\, \\frac{\\text{hours}}{\\text{day}}}{8 \\, \\frac{\\text{hours}}{\\text{dose}}} = 3 \\, \\frac{\\text{doses}}{\\text{day}}$$\nThe total daily amount for the second interval, denoted $T_2$, is the product of the same amount per dose ($A_{dose}$) and the new number of doses per day ($N_2$).\n$$T_2 = A_{dose} \\times N_2$$\n$$T_2 = 150,000 \\, \\frac{\\text{units}}{\\text{dose}} \\times 3 \\, \\frac{\\text{doses}}{\\text{day}} = 450,000 \\, \\frac{\\text{units}}{\\text{day}}$$\n\nThe problem asks for the two results, $T_1$ and $T_2$, to be presented as a row matrix. The first entry corresponds to the first seven days of life ($T_1 = 300,000$ units/day), and the second entry corresponds to the period thereafter ($T_2 = 450,000$ units/day).",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n300000  450000\n\\end{pmatrix}\n}\n$$"
        }
    ]
}